704 research outputs found
COVID-19 exacerbated inequalities in life expectancy in Denmark
No full textSocial inequalities in mortality expanded during the COVID-19 pandemic in Denmark. Cosmo Strozza, Serena Vigezzi, Julia Callaway, and José Manuel Aburto quantified life expectancy changes in 2020 and 2021 and underlying causes of death. COVID-19, as well as other causes, contributed to these changes
COVID-19 exacerbated inequalities in life expectancy in Denmark
No full textSocial inequalities in mortality expanded during the COVID-19 pandemic in Denmark. Cosmo Strozza, Serena Vigezzi, Julia Callaway, and José Manuel Aburto quantified life expectancy changes in 2020 and 2021 and underlying causes of death. COVID-19, as well as other causes, contributed to these changes
COVID-19 exacerbated inequalities in life expectancy in Denmark
No full textSocial inequalities in mortality expanded during the COVID-19 pandemic in Denmark. Cosmo Strozza, Serena Vigezzi, Julia Callaway, and José Manuel Aburto quantified life expectancy changes in 2020 and 2021 and underlying causes of death. COVID-19, as well as other causes, contributed to these changes
Location-Based Discovery and Network Handover Management for Heterogeneous IEEE 802.11ah IoT Applications
No full textThis research was funded by the Flemish IDEAL-IoT project (FWO SBO, grant nr. S004017N). The author Serena Santi is funded by the Flemish FWO SB grant (nr. 1S82120N). The author Filip Lemic was supported by the EU MSCA grant (nr. 893760). The computational resources were provided by the VSC (Flemish Supercomputer Center), funded by FWO and the Flemish Government -department EWI
Erratum: Lack of immunity against rubella among Italian young adults. [BMC Infect Dis., 17, (2017) (199)] Doi: 10.1186/s12879-017-2295-y
No full textAfter publication of this article [1], the authors noted that the given names and family names of all authors had been inverted, and are therefore incorrect in the original article. In the original article, the author names appear as the following: Gallone Maria Serena, Gallone Maria Filomena, Larocca Angela Maria Vittoria, Germinario Cinzia and Tafuri Silvio. However, this is incorrect, and the author names should appear as per the below: Maria Serena Gallone, Maria Filomena Gallone, Angela Maria Vittoria Larocca, Cinzia Germinario, Silvio Tafuri. The author names have been corrected in the author list and the citation for this Erratum
Comparative efficacy of epoetin alfa vs. darbepoetin in children with chronic kidney disease: a systematic review, meta-analysis and cost-effectiveness analysis
Full text linkBackground: Recombinant human erythropoietin (rHuEPO) and darbepoetin alfa (DA) are key treatments for anemia in individuals with chronic kidney disease (CKD), including children, but evidence comparing their efficacy in the pediatric population remains inconclusive. Methods: This systematic review, adhering to PRISMA guidelines, analyzed randomized controlled trials and observational studies comparing rHuEPO and DA in pediatric patients with CKD (≤ 18 years; ≥ 10 children per study), searched across medical databases and clinical trial registries until 31/12/2024. The Cochrane Risk of Bias was used for assessment. Meta-analysis evaluated hemoglobin (Hb) increase and cost-effectiveness using the incremental cost-effectiveness ratio. Results: From 1298 screened articles, 7 studies were included: 3 prospective studies, 2 randomized open-label non-inferiority trials, and 2 retrospective cohort studies, comprising 208 children for direct comparisons and 357 for transitioning studies. Meta-analysis found no significant Hb improvement differences between rHuEPO and DA after 21–28 weeks of treatment (DA + 0.15 g/dL, 95% CI − 0.22 to + 0.52). rHuEPO was more cost-effective than DA. Transitioning to DA increased Hb by + 0.93 g/dL (95% CI 0.53–1.33) in children with suboptimal levels, after 21–28 weeks of rHuEPO. The incremental cost-effectiveness ratio of switching to DA was ~ €340 per g/dL of Hb over 24 weeks. Conclusions: rHuEPO is the most cost-effective initial anemia treatment in pediatric CKD. However, transitioning to DA may be considered for patients who do not achieve adequate Hb response. The small number of randomized controlled trials (RCTs), variability in dose conversion, and study heterogeneity may limit generalizability. PROSPERO ID: CRD42023460872
Efficacy and safety of fenoldopam for the treatment of hypertensive crises in children with kidney disease: a retrospective study
Full text linkBackground: Hypertensive crises in children represent critical medical situations characterized by severe hypertension and potential organ damage. Fenoldopam, a dopaminergic medication, offers a viable therapeutic option for managing such clinical scenarios. We aimed to evaluate efficacy and safety of fenoldopam in the management of hypertensive urgencies and emergencies. Methods: This retrospective analysis focused on pediatric patients affected by acute or chronic kidney disease, aged 1 month–18 years, admitted to the Pediatric Nephrology and the Pediatric Intensive Care Unit at University-Hospital of Padua, Italy, who presented with a hypertensive crisis treated with fenoldopam between March 2010 and December 2022. Results: The study included 74 patients with median age 10 years (interquartile range [IQR] 4–15 years) who received 102 fenoldopam infusions. Seventy-two percent were already receiving antihypertensive treatment before admission. In all cases, fenoldopam was associated with a reduction of blood pressure (BP) after 8 h of treatment, but in 87% of patients reduction of the initial mean arterial pressure (MAP) was higher than 25% of calculated drop pressure. MAP normalized in 26% of cases after 24 h and in 35% after 48 h. Occurrence of hypotension was 7%, while hypokalemia was observed in 13% of cases. Patients who presented a MAP reduction not exceeding 25% of calculated drop pressure received a lower median fenoldopam dose (0.2 mcg/kg/min; IQR 0.1–0.2) compared with patients having a MAP reduction > 25% of calculated drop pressure (0.4 mcg/kg/min; IQR 0.2–0.6; p = 0.002). Conclusions: Fenoldopam seems effective and safe for the treatment of hypertensive crises in children with kidney disease, at a starting dose of 0.2 mcg/kg/min. Strict BP monitoring is required to identify possible excessive drop pressure in the first hours of infusion. Graphical abstract: (Figure presented.
Justice, markets, and the family: an interview with Serena Olsaretti
Full text linkSerena Olsaretti (Naples, Italy, 1971) is a political philosopher at
Pompeu Fabra University (UPF), where she holds a research
professorship with the Catalan Institute of Research and Advanced
Studies (ICREA). Before moving to Barcelona, she was University Senior
Lecturer at the Faculty of Philosophy of Cambridge University. She
obtained a BA, MPhil, and DPhil degree in political philosophy from
Oxford University. Her DPhil thesis was supervised by G.A. Cohen.
Olsaretti’s research interests range widely, including the ethics of
markets, justice and the family, feminist philosophy, theories of
responsibility, and theories of well-being. She is the author of Liberty,
desert and the market (2004), and the editor of Desert and justice (2003),
Preferences and well-being (2006), and the Oxford handbook of
distributive justice (forthcoming). Her work has appeared in various
journals, including Analysis, Economics & Philosophy, Philosophy & Public
Affairs, and Proceedings of the Aristotelian Society. Olsaretti is one of the
editors of Law, Ethics, and Philosophy. She is the principal investigator
of Family justice: an analysis of the normative significance of procreation
and parenthood in a just society, a research project funded by a
European Research Council (ERC) consolidator grant.
The Erasmus Journal for Philosophy and Economics (EJPE)
interviewed Olsaretti about becoming a political philosopher, her work
on the ethics of markets and justice and the family, the ERC-project that
she directs, her views on teaching, and her advice for political
philosophy graduates aspiring to an academic career.This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation programme (Grant Agreement Number: 648610)
Giurisprudenza romana nei papiri. Tracce per una ricerca
No full textThe volume presents a collection of essays devoted to circulation and transmission of Roman
legal knowledge in Late Antiquity, focusing on the description, edition and commentary of legal
fragments, on papyrus and parchment, from III to V c. AD; this period, between the classical age of
Roman legal jurisprudence and the great enterprise of the Digest of Justinian, is usually considered of
decadence in the traditional legal scholarship. The papyrus and parchment fragments, mostly found
in archaeological excavation in the Eastern Part of the Roman Empire or kept in Western Libraries
for centuries, contain texts different in topics and lengths: some are copies of works of classical
legal literature (e.g., Ulpian), some others are Greek or Latin-Greek legal commentaries; a few of
them bear text which are not known from other sources, therefore is not possible to guess if they are
original works or commentaries in somebody else work; there are excerpts from different authors
and works, interlinear and marginal glosses of considerable length. The same variety can be seen
in their book formats (from fine parchments books to re-used papyrus leaves, from pocket books to
wide margin pages, suitable to host long annotations) and scripts (from Latin legal uncial to cursive
scripts; a considerable bilingual and digraphical evidence is here discussed, too). All this diversity is
a significant witness of the lively word of Roman legal scholarship in Late Antiquity. Scholars from
different Italian and foreign universities (Bari, Naples, Parma, Pavia, Rome, Siena, Zurich) present
in this book the results of their investigations in the frame of the PRIN 2009 project ‘Legal literature
in Late Antiquity (III-V c. AD). History and Geography’. Ulrico Agnati (Parma) e Serena Ammirati
(Roma Tre-Pavia) present a re-edition and commentary of P.Oxy. XVII 2089, whose text is about
marital legacies. Author and title of the work are unknown. Sergio Alessandrì offer a new exegesis
of PSI XIV 1449, from book 32 of Ulpian, Ad edictum; Andrea Lovato discusses the contents of
P.Fay. 10 and P.Berol. inv. 11533, a papyrus fragment about imperial dispositions on the legacy of
the soldiers; and of Cod. Vind. 1b, which bears Ulpian Institutions; the essay of Federico Battaglia
(Zurich) focuses on the structure and the definitions of PSI XIII 1348; to Valerio Marotta (Pavia)
we owe a new commentary on P.Berol. inv. 6757, known as Fragmentum de iudiciis; Stefania
Pietrini (Siena)’s paper is about the meaning of the marginal glosses preserved through P.Ant. III
152, on dowry and the related legal actions; Jolanda Ruggiero (Roma, Sapienza) presents the wellknown
Fragments with the Sententiae of Paul, Leiden, BPL 2589. Fragments different in content
are nonetheless very important to reconstruct the legal thinking of Late Antiquity: Maria Chiara
Scappaticcio (Naples) edits and comments the legal glosses in P.Ryl. III 477, a papyrus collection
of Cicero’s speeches; Serena Ammirati offers a survey of bilingual Greek-Latin glossaries and their
graphic and textual interaction with legal fragments; Dario Mantovani (Pavia)’s reflections about the
origin of Digest offer a new insight on the continuity in the transmission of Roman classical legal
scholarship, which helps to frame all the fragments discussed in the book
- …
